drugset / Trial / NCT06161220
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
Timeline
- Start
- 2023-10-30
- Primary completion
- 2023-12-03
- Completion
- 2023-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbidopa | Unknown | 400 mg | — |
| Subject | Moxifloxacin | Small molecule | 400 mg | — |
Indications
No indication recorded.